Strategic F U N D

Improving access to quality public health supplies

he Strategic Fund, also known as the Regional Revolving Fund for Strategic Public Health Supplies, was created by PAHO in September 2000 to promote the acquisition of high quality medicines and essential public health supplies at affordable prices in the Americas.

What the Strategic Fund offers

- Technical cooperation: The main benefit for a Member State participating in the Strategic Fund is PAHO technical support in procurement planning, programming and forecasting to insure continuous availability of essential public health supplies.
- Affordability: PAHO can provide low cost essential public health supplies by taking advantage of the potential savings offered by economies of scale, and good quality (the SF uses prequalified suppliers which meet PAHO/WHO quality standards)

Product Categories

- Antiretrovirals
- First- and second-line antituberculars
- Antimalarials
- Antileishmanials
- Anti–Chagas
- Antineoplastics
- Blood products

- Plasma substitutes
- Cardiovascular medications
- Diagnostic medications
- Hypoglycemic agents
- Immunosuppressants

The list also includes:

- Diagnostic reagents and
- Insecticides

Users

Currently, 23 PAHO member countries acquire medications by means of an agreement with the Strategic Fund (see country members' map on inverse). The list of medications, supplies, reference prices, and procedures for initiating a purchase is available on the Strategic Fund website- www.paho.org/StrategicFund.





